Inactive Instrument

Highlights ISIS Pharmaceuticals, Inc. Nasdaq

Equities

US4643301090

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

North American Morning Briefing : Stock Futures -2-	Apr. 11	DJ
Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome	Apr. 07	CI
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial	Mar. 13	RE
Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224	Mar. 13	CI
Travere drug for rare kidney condition recommended for EU approval	Feb. 23	RE
Ionis Pharmaceuticals' Q4 Net Loss Narrows as Revenue Increases; Provides 2024 Revenue Guidance; Shares Gain Pre-Bell	Feb. 21	MT
Earnings Flash (IONS) IONIS PHARMACEUTICALS Posts Q4 Revenue $325M	Feb. 21	MT
Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Feb. 21	CI
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 30, 2023	Feb. 21	CI
Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS	Feb. 15	CI
GSK: fast track approval for hepatitis treatment in the USA	Feb. 12	CF
Ionis Pharma's genetic disease drug succeeds in late-stage study	Jan. 22	RE
Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema	Jan. 22	CI
Upcoming Key Inflation Data Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday	Dec. 22	MT
Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA	Dec. 21	CI
US FDA approves Ionis-AstraZeneca's nerve disease drug	Dec. 21	RE
Ionis Pharmaceuticals Signs Europe Licensing Deal With Otsuka for Donidalorsen in Hereditary Angioedema	Dec. 18	MT
Ionis Announces European Licensing Agreement with Otsuka for Donidalorsen in Hereditary Angioedema	Dec. 18	CI
Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome	Nov. 11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ISIS Pharmaceuticals, Inc. Nasdaq

Equities

US4643301090

Highlights

Filters